Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy

Circulation: Heart Failure

Volumn 5, Issue 1, 2012, Pages 10-16

  Rogers, Joseph G ^a,b   Bostic, Robin R ^c   Tong, Kuo B ^d   Adamson, Rob ^e   Russo, Mark ^f   Slaughter, Mark S ^g  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c THORATEC CORPORATION   (United States)

^d Quorum Consulting Inc   (United States)

^e SHARP MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g University of Louisville School of Medicine   (United States)

Author keywords

Cost effectiveness; Heart failure; Heart assist device

Indexed keywords

CARDIOVASCULAR AGENT;

ARTICLE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ASSIST DEVICE; HEART FAILURE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MEDICARE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PAYMENT; PULSATILE FLOW LEFT VENTRICULAR ASSIST DEVICE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; ECONOMICS; MORTALITY; REIMBURSEMENT; UNITED STATES;

COST-BENEFIT ANALYSIS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; PROSPECTIVE PAYMENT SYSTEM; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84859633891     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.962951     Document Type: Article

References (24)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics: 2010 update: A report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Deng MC, Naka Y. Advanced Heart Failure: Mechanical Circulatory Support Therapy in Advanced Heart Failure. London Imperial College Press, London, United Kingdom; 2007.
3. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26:447-462. (Pubitemid 351704856)
4. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Long-term use of a left ventricular assist device for end-stage heart failure N Engl J Med. 2001; 345:1435-1443.
5. Oz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons R, Aaronson K, Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson J, Rose EA, Moskowitz AJ. Left ventricular assist devices as permanent heart failure therapy: The price of progress. Ann Surg. 2003;238:577-583.
6. Special report: Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Technol Eval Cent Assess Program Exec Sumn. 2004;19:1.
7. Miller LW, Nelson KE, Bostic RR, Tong K, Slaughter MS, Long JW. Hospital costs for left ventricular assist devices for destination therapy: Lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant. 2006;25:778-784. (Pubitemid 43963374)
8. Clegg AJ, Scott DA, Loveman E, Colquitt J, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: A systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23: 261-268. (Pubitemid 46642732)
9. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM III, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361: 2241-2251.
10. Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, Edwards BS, Park S, John R, Conte JV, Farrar DJ, Slaughter MS. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826-1834.
11. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell CT Jr, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation. 2009;120:2352-2357.
12. Gohler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility estimates for decision-analytic modeling in chronic heart failure: Health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12:185-187.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258. (Pubitemid 26337709)
14. Slaughter M, Bostic R, Tong K, Russo M, Rogers J. Temporal changes in hospital costs for left ventricular assist device placement J Card Surg. 2011;26:535-541.
15. Centers for Medicare and Medicaid Services. Standard Analytic File, 2008. Centers for Medicare and Medicaid Services, Baltimore, MD.
16. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: Results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009;119:969-977.
17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009; 360:1418-1428.
18. Medicare Program; changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates; payments for graduate medical education in certain emergency situations; changes to disclosure of physician ownership in hospitals and physician self-referral rules; updates to the long-term care prospective payment system; updates to certain IPPSexcluded hospitals; and collection of information regarding financial relationships between hospitals; final rule. Federal Register. 73; 8-19-2008.
19. Russo MJ, Gelijns AC, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, Ascheim DD, Hong KN, Oz MC, Moskowitz AJ, Rose EA, Miller LW. The cost of medical management in advanced heart failure during the final two years of life. J Card Fail. 2008;14:651-658.
20. Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Ann Thorac Surg. 2001;71:S195-S198. (Pubitemid 32216219)
21. Gelijns AC, Richards AF, Williams DL, Oz MC, Oliveira J, Moskowitz AJ. Evolving costs of long-term left ventricular assist device implantation. Ann Thorac Surg. 1997;64:1312-1319. (Pubitemid 27522625)
22. United States Deptartment of Labor, Bureau of Labor Statistics. Consumer price index (Medicare care services). http://www.bls.gov/bls/inflation.htm. Accessed June 22, 2010.
23. Fang JC. Rise of the machines: Left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med. 2009;361: 2282-2285.
24. Simoens S. How to assess the value of medicines? Front Pharmacol. 2010;1:115.